Colleen Erin Snow

Array ( [id] => 18946994 [patent_doc_number] => 11890266 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-06 [patent_title] => Ophthalmic compositions including levodopa, an antioxidant and an aqueous carrier [patent_app_type] => utility [patent_app_number] => 17/103709 [patent_app_country] => US [patent_app_date] => 2020-11-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 14546 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17103709 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16686694 [patent_doc_number] => 20210069169 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => PHARMACEUTICAL COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 16/951783 [patent_app_country] => US [patent_app_date] => 2020-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24654 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16951783 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16688240 [patent_doc_number] => 20210070716 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => ANTI-INFLAMMATORY AGENTS [patent_app_type] => utility [patent_app_number] => 16/951701 [patent_app_country] => US [patent_app_date] => 2020-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52368 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16951701 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18589131 [patent_doc_number] => 11738003 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-29 [patent_title] => Method for administration [patent_app_type] => utility [patent_app_number] => 16/951153 [patent_app_country] => US [patent_app_date] => 2020-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 2883 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16951153 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18503542 [patent_doc_number] => 11701332 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-18 [patent_title] => Methods and compositions for treating female sexual interest and arousal disorder [patent_app_type] => utility [patent_app_number] => 16/952018 [patent_app_country] => US [patent_app_date] => 2020-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5722 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16952018 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16954821 [patent_doc_number] => 11058648 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-13 [patent_title] => Bupropion as a modulator of drug activity [patent_app_type] => utility [patent_app_number] => 17/099226 [patent_app_country] => US [patent_app_date] => 2020-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 24 [patent_no_of_words] => 63712 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17099226 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18852661 [patent_doc_number] => 11850213 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-12-26 [patent_title] => Ophthalmic compositions of rifamycins and uses thereof [patent_app_type] => utility [patent_app_number] => 17/098272 [patent_app_country] => US [patent_app_date] => 2020-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 8 [patent_no_of_words] => 9876 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 114 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17098272 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16837763 [patent_doc_number] => 20210145775 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-20 [patent_title] => Treatment of intestinal barrier dysfunction and associated diseases [patent_app_type] => utility [patent_app_number] => 17/096385 [patent_app_country] => US [patent_app_date] => 2020-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5401 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17096385 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16671258 [patent_doc_number] => 20210060021 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => Method of Adjuvant Cancer Treatment [patent_app_type] => utility [patent_app_number] => 17/095200 [patent_app_country] => US [patent_app_date] => 2020-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5089 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17095200 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19666091 [patent_doc_number] => 12178811 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-31 [patent_title] => Methods of treating depressive disorders [patent_app_type] => utility [patent_app_number] => 17/093183 [patent_app_country] => US [patent_app_date] => 2020-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 4 [patent_no_of_words] => 9872 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17093183 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16805988 [patent_doc_number] => 20210128541 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => ANDROGEN RECEPTOR INHIBITORS FOR THE TREATMENT OF NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN SUBJECTS WITH SEVERE HEPATIC IMPAIRMENT [patent_app_type] => utility [patent_app_number] => 17/089393 [patent_app_country] => US [patent_app_date] => 2020-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19231 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17089393 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17858508 [patent_doc_number] => 11439646 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-13 [patent_title] => Anti-proliferative agents for treating PAH [patent_app_type] => utility [patent_app_number] => 17/089154 [patent_app_country] => US [patent_app_date] => 2020-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 34 [patent_no_of_words] => 7558 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17089154 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18193583 [patent_doc_number] => 20230047102 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-16 [patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING N-[1-(5-CYANO-PYRIDIN-2-YLMETHYL)-1H-PYRAZOL-3-YL]-2-[4-(1-TRIFLUOROMETHYL-CYCLOPROPYL)-PHENYL]-ACETAMIDE [patent_app_type] => utility [patent_app_number] => 17/786965 [patent_app_country] => US [patent_app_date] => 2020-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8729 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17786965 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16805958 [patent_doc_number] => 20210128511 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => PRODRUG COMPOSITIONS AND METHODS OF TREATMENT [patent_app_type] => utility [patent_app_number] => 17/086409 [patent_app_country] => US [patent_app_date] => 2020-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34174 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -74 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17086409 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17828374 [patent_doc_number] => 20220265678 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => PREFERRED ORAL TESTOSTERONE UNDECANOATE THERAPY TO ACHIEVE TESTOSTERONE REPLACEMENT TREATMENT [patent_app_type] => utility [patent_app_number] => 17/085824 [patent_app_country] => US [patent_app_date] => 2020-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16934 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17085824 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16791665 [patent_doc_number] => 20210121482 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-29 [patent_title] => WITHANOLIDES FOR THE TREATMENT OF CACHEXIA [patent_app_type] => utility [patent_app_number] => 17/082430 [patent_app_country] => US [patent_app_date] => 2020-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25374 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17082430 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16621381 [patent_doc_number] => 20210040034 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES [patent_app_type] => utility [patent_app_number] => 17/077530 [patent_app_country] => US [patent_app_date] => 2020-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15092 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17077530 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16726475 [patent_doc_number] => 20210093622 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-01 [patent_title] => USE OF PRIDOPIDINE FOR THE TREATMENT OF ANXIETY AND DEPRESSION [patent_app_type] => utility [patent_app_number] => 17/074901 [patent_app_country] => US [patent_app_date] => 2020-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10932 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17074901 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16718482 [patent_doc_number] => 20210085629 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-25 [patent_title] => METHODS OF REDUCING OR PREVENTING OXIDATION OF SMALL DENSE LDL OR MEMBRANE POLYUNSATURATED FATTY ACIDS [patent_app_type] => utility [patent_app_number] => 17/074505 [patent_app_country] => US [patent_app_date] => 2020-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31278 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17074505 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16776489 [patent_doc_number] => 20210113566 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-22 [patent_title] => USE OF JAK1 INHIBITORS FOR THE TREATMENT OF CUTANEOUS LUPUS ERYTHEMATOSUS AND LICHEN PLANUS (LP) [patent_app_type] => utility [patent_app_number] => 17/072093 [patent_app_country] => US [patent_app_date] => 2020-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14958 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17072093 [rel_patent_id] =>[rel_patent_doc_number] =>)